

Country Demographics <sup>1, 2</sup>	
Total Population (2018) <sup>1</sup>	1,136,191
Urban Population (% of total, 2018) <sup>1</sup>	23.8%
Health expenditure per capita (\$US, 2016) <sup>1</sup>	\$220.6
Health expenditure, total (% of GDP, 2016) <sup>1</sup>	7.7%
Total births (2013) <sup>2</sup>	NR
Surviving Infants (2013) <sup>2</sup>	NR
Life expectancy at birth (years, 2017) <sup>1</sup>	58.3 years
Number of districts (2013) <sup>2</sup>	NR


HBsAg Prevalence <sup>3</sup>	
Pre-vaccine HBsAG+ (%)	NR

Liver Cancer as Cause of Cancer Death (in Men) <sup>4</sup>	
Year: 2018	Ranking: 3

2018 Country Comparison in African Region (47 Countries) <sup>5</sup>				
	Eswatini	Number of countries with reported coverage	Highest reported coverage in AFR	Lowest reported coverage in AFR
HepB3 <sup>5</sup>	90%	47	99% (Cabo Verde, Seychelles)	25% (Equatorial Guinea)
HepB BD <sup>5</sup>	NR	4	99% (Algeria)	63% (Senegal)

Hepatitis B Immunization Coverage <sup>5</sup>																				
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	
HepB3 <sup>5</sup>	83%	86%	88%	90%	93%	95%	93%	92%	90%	88%	89%	91%	95%	98%	98%	90%	90%	90%	90%	
HepB BD <sup>5</sup>	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
BCG <sup>5</sup>	88%	89%	90%	91%	92%	93%	94%	95%	96%	97%	98%	98%	99%	99%	99%	98%	97%	98%	98%	

Eswatini: HepB3



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAG= HepB surface antigen. Data Compiled by Asian Liver Center at Stanford University 2019: World DataBank: World Development Indicators database<sup>1</sup>, WHO Immunization Summary: A statistical reference containing data through 2013<sup>2</sup>, WHO Public Health Significance, Targets, Strategies: HBV country profiles<sup>3</sup>, Global Cancer Observatory: Cancer Today-IARC<sup>4</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates<sup>5</sup>